Finerenone is the first therapy targeting the mineralocorticoid receptor pathway to demonstrate cardiovascular benefits in heart failure patients
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Ryght AI tackles these hurdles with its AI Site Twin platform
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The study met its primary endpoint and all 11 secondary efficacy endpoints
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Growing patent filings and tier-2 innovators reflect expanding national research base
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
Subscribe To Our Newsletter & Stay Updated
